Publicaciones en colaboración con investigadores/as de Hospital General Universitario Gregorio Marañón (19)

2022

  1. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

    European Journal of Cancer, Vol. 175, pp. 110-119

2021

  1. Circulating levels of the interferon-γ-regulated chemokines cxcl10/cxcl11, il-6 and hgf predict outcome in metastatic renal cell carcinoma patients treated with antiangiogenic therapy

    Cancers, Vol. 13, Núm. 11

2020

  1. ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort

    Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 140-148

  2. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma

    International Journal of Cancer, Vol. 146, Núm. 5, pp. 1435-1444

2019

  1. Deep sequencing reveals microRNAs predictive of antiangiogenic drug response

    JCI Insight, Vol. 1, Núm. 10

  2. Observational Prospective Study to Determine the Evolution of the Symptomatic Profile of Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients and Its Relation to the Control of the Disease

    Advances in Therapy, Vol. 36, Núm. 6, pp. 1497-1508

2018

  1. Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies

    Expert Opinion on Drug Safety, Vol. 17, Núm. 6, pp. 573-579

  2. Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: Toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii286

  3. Radium-223 international early access program: Results from the Spanish subset

    Future Oncology, Vol. 14, Núm. 1, pp. 41-50

2017

  1. A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01)

    European Urology Focus, Vol. 3, Núm. 4-5, pp. 430-436

  2. Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer

    European Urology Focus, Vol. 3, Núm. 2-3, pp. 280-286

  3. Recent advances in genitourinary tumors: A review focused on biology and systemic treatment

    Critical Reviews in Oncology/Hematology, Vol. 113, pp. 171-190

2016

  1. Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations

    Targeted Oncology, Vol. 11, Núm. 2, pp. 129-141

2014

  1. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma

    PLoS ONE, Vol. 9, Núm. 1

2013

  1. Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma

    Annals of Oncology, Vol. 24, Núm. 9, pp. 2409-2414

  2. Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study

    British Journal of Cancer, Vol. 108, Núm. 12, pp. 2565-2572

2012

  1. Recommendations for the optimal management of early and advanced urothelial carcinoma

    Cancer Treatment Reviews, Vol. 38, Núm. 5, pp. 431-441

2011

  1. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: A multicentre, observational, prospective study

    The Lancet Oncology, Vol. 12, Núm. 12, pp. 1143-1150

2009

  1. Professional burnout among Spanish medical oncologists

    Clinical and Translational Oncology, Vol. 11, Núm. 2, pp. 86-90